To include your compound in the COVID-19 Resource Center, submit it here.

Trapped to the max

Companies faced with manufacturing or formulation constraints early in the clinical development of a compound have a tough decision to make. Should they wait to run dose-ranging trials until they can manufacture enough product to push the dose to the limit? Or should they go

Read the full 455 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE